Clinical Trial Update: Treatment for Aggression and Agitation in Patients With Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a treatment for aggression and agitation in Alzheimer's disease by Eli Lilly has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-11-29